BIONTECH SE-ADR (BNTX)

US09075V1026 - ADR

117.53  +0.33 (+0.28%)

Fundamental Rating

4

Taking everything into account, BNTX scores 4 out of 10 in our fundamental rating. BNTX was compared to 570 industry peers in the Biotechnology industry. While BNTX has a great health rating, its profitability is only average at the moment. BNTX does not seem to be growing, but still is valued expensively.



4

1. Profitability

1.1 Basic Checks

BNTX had negative earnings in the past year.
In the past year BNTX had a positive cash flow from operations.
BNTX had positive earnings in 4 of the past 5 years.
In multiple years BNTX reported negative operating cash flow during the last 5 years.

1.2 Ratios

With an excellent Return On Assets value of -2.27%, BNTX belongs to the best of the industry, outperforming 91.36% of the companies in the same industry.
Looking at the Return On Equity, with a value of -2.64%, BNTX belongs to the top of the industry, outperforming 93.30% of the companies in the same industry.
Industry RankSector Rank
ROA -2.27%
ROE -2.64%
ROIC N/A
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BNTX's Profit Margin has improved in the last couple of years.
BNTX's Gross Margin of 85.27% is amongst the best of the industry. BNTX outperforms 88.89% of its industry peers.
BNTX's Gross Margin has been stable in the last couple of years.
BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%

7

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTX has been reduced compared to 1 year ago.
Compared to 5 years ago, BNTX has more shares outstanding
BNTX has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 7.15 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX's Altman-Z score of 7.15 is amongst the best of the industry. BNTX outperforms 82.54% of its industry peers.
BNTX has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.11, BNTX belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
BNTX has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.11
Altman-Z 7.15
ROIC/WACCN/A
WACC6.82%

2.3 Liquidity

A Current Ratio of 7.54 indicates that BNTX has no problem at all paying its short term obligations.
The Current ratio of BNTX (7.54) is better than 70.55% of its industry peers.
A Quick Ratio of 7.40 indicates that BNTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.40, BNTX is in the better half of the industry, outperforming 69.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.4

3

3. Growth

3.1 Past

BNTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.52%.
The Earnings Per Share has been growing by 279.64% on average over the past years. This is a very strong growth
Looking at the last year, BNTX shows a very negative growth in Revenue. The Revenue has decreased by -77.94% in the last year.
Measured over the past years, BNTX shows a very strong growth in Revenue. The Revenue has been growing by 97.22% on average per year.
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%

3.2 Future

BNTX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -54.67% yearly.
The Revenue is expected to decrease by -2.06% on average over the next years.
EPS Next Y-182.94%
EPS Next 2Y-69.56%
EPS Next 3Y-39.4%
EPS Next 5Y-54.67%
Revenue Next Year-39.24%
Revenue Next 2Y-22.5%
Revenue Next 3Y-15.93%
Revenue Next 5Y-2.06%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

BNTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BNTX is cheaper than 98.06% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.46
EV/EBITDA N/A

4.3 Compensation for Growth

BNTX's earnings are expected to decrease with -39.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.56%
EPS Next 3Y-39.4%

0

5. Dividend

5.1 Amount

No dividends for BNTX!.
Industry RankSector Rank
Dividend Yield N/A

BIONTECH SE-ADR

NASDAQ:BNTX (12/3/2024, 12:39:48 PM)

117.53

+0.33 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap28.32B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.27%
ROE -2.64%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 85.27%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.54
Quick Ratio 7.4
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5Y
EPS Q2Q%
EPS Next Y-182.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y